KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study

Table 4 KRAS genotype frequencies and HR status and HER2 status according to HRT stratification

Study population	Genotype	Frequency		p	Frequency p		p
		N(%)		value	N(%)		value
		HR⁺	HR^-		HER2⁺	HER2^-
All	wild(TT)	363(82.9)	69(83.1)	0.955	49(77.8)	372(84.0)	0.218
	variable(TG/GG)	75(17.1)	14(16.9)		14(22.2)	71(16.0)
Nonusers: HRT < 1 year	wild(TT) variable(TG/GG)	250(81.7) 56(18.3)	52(85.2) 9(14.8)	0.508	41(83.7) 8(16.3)	255(82.8) 53(17.2)	0.879
Users: HRT 1 years	wild(TT)	113(85.6)	17(77.3)	0.318	8(57.1)	117(86.7)	0.004
	variable(TG/GG)	19(14.4)	5(22.7)		6(42.9)	18(13.3)

ISSN: 1471-2407